MDS Symposium 2013 Update – Day One The MDS Beacon Specifically, the Canadian researchers found that 68 percent of patients responded to treatment with anti-thymocyte globulin (ATG) or cyclosporine (Sandimmune) for a median of 33 months. The two-year progression-free survival rate was 85 percent, and ... |
